The discovery and preclinical efficacy of ANS-858, a proprietary, selective, reversible, orally bioavailable ALDH2 inhibitor will be presented at 48th Annual Scientific Meeting of the Research Society on Alcohol. SAN FRANCISCO, April 2, 2025 /PRNewswire/ -- Amygdala Neurosciences, Inc., a...
Read More Details
Finally We wish PressBee provided you with enough information of ( Amygdala Neurosciences Selects ANS-858 for Clinical Development as a Novel ALDH2 Inhibitor for Substance Use Disorder )
Also on site :
- Indian parliament’s lower house passes controversial Muslim endowments bill
- Danish prime minister visits Greenland as Trump seeks control of the Arctic territory
- Egypt climbs up in FIFA World Rankings